Amgen's Lumakras facing FDA advisory panel for full approval
Mario Tama/Getty Images News

The US FDA will hold an advisory committee meeting to discuss converting the accelerated approval of Amgen's (NASDAQ:AMGN) non-small cell lung cancer treatment Lumakras (sotorasib) to full approval.
The meeting of the Oncologic Drugs Advisory Committee will take place on Oct. 5.

The KRASG12C inhibitor was granted accelerated approval in the US for in May 2021.
Lumakras brought in $77M in global sales in Q2.


More on Amgen

Improved Outlook For Horizon Therapeutics And Amgen
Amgen Is Back!
Amgen Gives You Growth, Dividend Growth, And Value
Amgen says FTC has ignored commitments it made to address Horizon deal concerns (update)
Seeking Alphaâs Quant Rating on Amgen